Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Cantor Fitzgerald
Covington
Merck
Colorcon
Farmers Insurance
Chinese Patent Office
Fish and Richardson

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,148,359

« Back to Dashboard

Which drugs does patent 7,148,359 protect, and when does it expire?

Patent 7,148,359 protects VIEKIRA XR, VIEKIRA PAK (COPACKAGED), KALETRA, NORVIR, and TECHNIVIE, and is included in five NDAs.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 7,148,359
Title:Polymorph of a pharmaceutical
Abstract:A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
Inventor(s): Chemburkar; Sanjay R. (Gurnee, IL), Patel; Ketan (Arlington Heights, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:11/122,300
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,148,359
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 7,148,359

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,148,359

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,193,367 Polymorph of a pharmaceutical ➤ Sign Up
9,255,092 Polymorph of a pharmaceutical ➤ Sign Up
6,894,171 Polymorph of a pharmaceutical ➤ Sign Up
8,674,112 Polymorph of a pharmaceutical ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
Farmers Insurance
Deloitte
QuintilesIMS
Boehringer Ingelheim
Healthtrust
Fish and Richardson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.